The conference call highlighted significant progress in Alzheimer’s treatment development, including promising trial results and a new patent. Financial stability and strategic clinical trials were also emphasized. However, increased expenses, net losses, and delays in certain programs were noted as challenges. Overall, the sentiment is cautiously optimistic, reflecting both achievements and areas needing further clarity.

Company Guidance

During the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call, Dr. Christopher Missling, President and CEO, provided updates on the company's progress in Alzheimer's treatment development. The long-term data from the Phase 2b/3 ATTENTION-AD open-label extension trial showed a significant reduction in clinical decline over three years, with blarcamesine slowing clinical progression by 36.3% at 48 weeks for the overall group and 49.8% for the SIGMAR1 wild-type gene group. Financially, Anavex reported a cash position of $120.8 million as of December 31, 2024, with an operating cash use of $12.1 million during the quarter and a four-year cash runway at the current utilization rate. R&D expenses increased to $10.4 million from $8.7 million the previous year, contributing to a net loss of $12.1 million or $0.14 per share. Additionally, Anavex received a new U.S. patent for the crystalline forms of the dihydrogen phosphate salt of ANAVEX freebase, projected to last until July 2039, covering neurodegenerative disorder treatments. The company anticipates results from the Phase 2 ANAVEX 3-71 schizophrenia study in H1 2025 and is preparing for further regulatory submissions and stakeholder engagements globally.

Positive Phase 2b/3 Alzheimer’s Trial Results

The Phase 2b/3 trial for blarcamesine showed a significant reduction in clinical decline for early Alzheimer’s disease patients, with a 36.3% slowing in clinical progression at 48 weeks and 49.8% for the SIGMAR1 wild-type gene group.

Successful Publication and Stakeholder Support

Results from the Alzheimer’s trial were published in The Journal of Prevention of Alzheimer Disease. The company is receiving growing support from stakeholders and advocacy groups for their treatment approach.

New Patent Issuance

Anavex was granted a new U.S. patent expected to last until July 2039, covering crystalline polymorph compositions for neuroprotection and treatment of neurodegenerative disorders.

Strong Financial Position

Anavex reported a cash position of $120.8 million with no debt, providing an estimated runway of approximately four years.

Ongoing Clinical Developments

ANAVEX 3-71 Phase 2 study in schizophrenia is progressing, with results expected in the first half of 2025.

---

Anavex Life Sciences (AVXL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AVXL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 08, 2025	2025 (Q2)	-0.15 / -	-0.13	―	―	―
Feb 12, 2025	2025 (Q1)	-0.17 / -0.14	-0.11	-27.27% (-0.03)	―
Dec 23, 2024	2024 (Q4)	-0.16 / -0.14	-0.12	-16.67% (-0.02)	―
Aug 06, 2024	2024 (Q3)	-0.16 / -0.14	-0.14	0.00% (0.00)	―
May 09, 2024	2024 (Q2)	-0.11 / -0.13	-0.17	23.53% (+0.04)	―
Feb 07, 2024	2024 (Q1)	-0.14 / -0.11	-0.17	35.29% (+0.06)	―
Nov 27, 2023	2023 (Q4)	-0.15 / -0.12	-0.18	33.33% (+0.06)	―
Aug 08, 2023	2023 (Q3)	-0.17 / -0.14	-0.16	12.50% (+0.02)	―
May 09, 2023	2023 (Q2)	-0.19 / -0.17	-0.14	-21.43% (-0.03)	―	―
Feb 07, 2023	2023 (Q1)	-0.19 / -0.17	-0.14	-21.43% (-0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

AVXL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 12, 2025	$8.29	$8.70	+4.95%
Dec 23, 2024	$8.63	$11.18	+29.55%
Aug 06, 2024	$6.45	$6.82	+5.74%
May 09, 2024	$3.71	$3.88	+4.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---